Skip to Content

Intersect ENT, Inc.

Merger

  • Date:
  • 8/6/2021
  • Company Name:
  • Intersect ENT, Inc.
  • Stock Symbol:
  • XENT
  • Company Name - Buyer:
  • Medtronic plc
  • Stock Symbol - Buyer:
  • MDT
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 8/6/2021

Case Finder

Locate any case using the tools below.

NEW YORK, August 6, 2021 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Intersect ENT, Inc. (NASDAQ: XENT) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Medtronic plc (NYSE: MDT).

On August 6, 2021, Intersect ENT announced that it had entered into an agreement to be acquired by Medtronic in a deal valued at approximately $1.1 billion.  Pursuant to the merger agreement, Intersect ENT stockholders will receive $28.25 in cash for each share of Intersect ENT common stock owned.  The deal is scheduled to close in the second half of 2021.

Bragar Eagel & Squire is concerned that Intersect ENT’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Intersect ENT’s stockholders.
 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Intersect ENT. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: